Background: The heart relies on continuous energy production and imbalances herein impair cardiac function directly. The tricarboxylic acid (TCA) cycle is the primary means of energy generation in the healthy myocardium, but direct noninvasive quantification of metabolic fluxes is challenging due to the low concentration of most metabolites. Hyperpolarized C]citrate was dynamically detected in vivo with a time resolution of 3 s. Different kinetic models were established and evaluated to determine the metabolic fluxes by simultaneously fitting the evolution of the 13 C labeling in acetate, acetylcarnitine, and citrate. V TCA was estimated to be 6.7 ± 1.7 μmol · g −1 · min −1 (dry weight), and was best estimated with a model using only the labeling in citrate and acetylcarnitine, independent of the precursor. The TCA cycle rate was not linear with the citrate-to-acetate metabolite ratio, and could thus not be quantified using a ratiometric approach. The 13 C signal evolution of citrate, i.e. citrate formation was independent of the amount of injected acetate, while the 13 C signal evolution of acetylcarnitine revealed a dose dependency with the injected acetate. The 13 C labeling of citrate did not correlate to that of acetylcarnitine, leading to the hypothesis that acetylcarnitine formation is not an indication of mitochondrial TCA cycle activity in the heart. Conclusions: Hyperpolarized [1-13 C]acetate is a metabolic probe independent of pyruvate dehydrogenase (PDH) activity. It allows the direct estimation of V TCA in vivo, which was shown to be neither dependent on the administered acetate dose nor on the 13 C labeling of acetylcarnitine. Dynamic 13 C MRS coupled to the injection of hyperpolarized [1-
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Introduction
To ensure contractile performance and support myocardial workload, the heart is in continuous need for energy sources that can supply adenosine triphosphate (ATP). A large fraction of myocardial ATP is generated through the tricarboxylic acid (TCA) cycle, the rate of which reflects the myocardial oxygen consumption [1] . Since the flux through the TCA cycle (V TCA ) is tightly linked to the mechanical workload of the heart, variations in V TCA are indicative of impaired myocardial metabolism and function. In the healthy myocardium, fatty acids are the preferred metabolic substrates but the propensity of the heart to extract energy from this type of fuel can be strongly altered in cardiac diseases. Acetate, although not a physiological substrate for the heart, has been shown to be a revealing tracer for assessing myocardial oxidative metabolism via positron emission tomography (PET) [2] and 13 C magnetic resonance spectroscopy (MRS) [1, 3, 4] . It is the shortest fatty acid and its uptake into the heart occurs through simple diffusion, its exchange between plasma and tissue only depending on the concentration gradient [5] . It is an effective oxidizable substrate formed endogenously that can be activated to acetylCoA via cytosolic or mitochondrial acetylCoA synthetase [6, 7] . The cytosolic variant of acetylCoA synthetase is mainly present in the liver, while the mitochondrial variant is abundant in the heart and muscle and provides acetylCoA that is utilized mainly for oxidation under ketogenic conditions [7] . AcetylCoA enters the tricarboxylic acid (TCA) cycle as citrate via an irreversible condensation with oxaloacetate catalyzed by citrate synthase. Since the inner mitochondrial membrane is impermeable to acetylCoA, an excess in acetylCoA can be transferred to the cytosol via a carnitine mediated acetyltransferase system [8] . The conversion of acetylCoA to acetylcarnitine is catalyzed by carnitine acetyl transferase (CAT), an enzyme largely found in heart mitochondria, peroxisomes, the endoplasmic reticular lumen but not in the cytosol [9, 10] . The shuttling of acetylcarnitine across mitochondrial membranes is an exchange process mediated by acetylcarnitine translocase (ATL). The reported absence of CAT from the cytosol, may suggest two metabolic routes of acetate, (i) passing by the peroxisomal centers to enter the mitochondria as acetylcarnitine, or (ii) a direct entry via mitochondrial ACS. There have been conflicting reports on the involvement of CAT and acetylcarnitine in the transfer of acetyl groups from peroxisomes to the cytosol as discussed in [11] , and therefore the conversion of acetate to acetylCoA via mitochondrial ACS seems most likely (Fig. 1) .
The dynamic aspect of in vivo 13 C MRS following metabolic substrate injection and its large chemical shift range, can provide unique insights into the metabolic state of the heart [1, [12] [13] [14] [15] . However, because of their inherent low concentrations, TCA cycle intermediates cannot be detected in vivo using thermally polarized 13 C-labeled substrates.
Instead, V TCA is estimated from the kinetics of incorporation of 13 C labels into glutamate via an isotopic exchange with 2-oxoglutarate [13, 14, 16, 17] . This indirect assessment not only involves TCA cycle activity, but also the oxoglutarate-malate carrier, since a large portion of the detected glutamate is located in the cytosol [18, 19] . Therefore, variations observed in the 13 C labeling dynamics of glutamate may indicate perturbations in metabolic intermediate pool size changes or membrane transport as in the ischemia-reperfusion model, where it was found that the rate of glutamate labeling decreased while V TCA remained normal [20] . The measurement of label incorporation into TCA cycle intermediates such as citrate, which is predominantly mitochondrial, would enable a direct estimation of V TCA .
Hyperpolarization via dissolution dynamic nuclear polarization (DNP) increases the sensitivity of 13 C MRS by several orders of magnitude and allows for the detection of less abundant metabolites in vivo [21] . The technique provides unique insights into important questions regarding myocardial metabolism, substrate preference, pharmacological intervention, and the ability to differentiate between normal and pathological metabolism [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . Pyruvate is by far the most widely used hyperpolarized 13 C substrate and it can be served as a probe for mitochondrial oxidative flux [34] . The entry of the 13 C label into the TCA cycle via acetylCoA is however dependent on the flux through pyruvate dehydrogenase (PDH), an enzyme that is tightly regulated and will hinder the direct assessment of V TCA . Unlike pyruvate, acetate uptake is independent of PDH activity. A study of hyperpolarized [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate metabolism in resting rat skeletal muscle showed that the rate of acetylcarnitine 13 C labeling can be directly translated to the metabolic flux through ACS [35] . However, despite the fact that [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetylCoA was detected in the mouse heart and liver following the injection of hyperpolarized [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate [36] , 13 C label incorporation from acetate into myocardial TCA cycle intermediates has to date not been reported in vivo. This is most likely due to their low concentration combined with their spectral proximity to the large 13 C resonance of the injected precursor. This is supported by the in vivo data obtained following the injection of hyperpolarized [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]butyrate in which citrate was clearly observed [32, 37] .
The aim of the present study was to take advantage of the sensitivity gain provided by hyperpolarization together with an increased chemical-shift resolution at high field to determine, in a single oneminute 13 C MRS experiment, myocardial TCA cycle flux in vivo using hyperpolarized [1-13 C]acetate as a metabolic substrate.
Methods

Animals
All animal experiments were conducted according to the Swiss federal ethical guidelines and were approved by the local regulatory body. Male Sprague Dawley rats (300 g) were anesthetized with 1.5% isoflurane in oxygen (n = 12). A catheter was placed into the femoral vein for intravenous delivery of the acetate solution. A second catheter was placed in the artery to monitor the blood pressure, which was used as a cardiac triggering signal and for blood sampling. Animals were placed and immobilized in a homebuilt holder to minimize potential motion during MRI and MRS acquisitions. Body temperature was maintained at 37°C using a warm water circulation system. Arterial blood pressure, heart rate, and respiratory rate were continuously monitored with an animal monitoring system (SA Instruments, NY, USA). Arterial pH and pressures of O 2 and CO 2 were measured using a blood gas analyzer (AVL Compact 3, Diamond Diagnostics, MA, USA). The rate-pressure-product (RPP) was determined from the arterial blood pressure and the heart rate. A summary of physiological parameters can be found in Table 1 . 
Sample preparation and hyperpolarization protocol
Unless otherwise specified, all chemicals were purchased from Sigma-Aldrich (Buchs, Switzerland). Sodium [1- 13 C]acetate was dissolved to a concentration of 4.5 M in a 1:2 mixture of fully deuterated ethanol (d 6 -EtOD) and water (D 2 O) containing 33 mM of TEMPO (2,2,6,6-tetramethylpiperidine-1-oxyl) free radical. A total volume of 300 μL of this solution was inserted, in the form of 10 μL frozen beads (prepared in liquid nitrogen), into a 5 T custom-designed DNP polarizer prefilled with liquid helium [38] . The 13 C nuclei were dynamically polarized for 2 h at 1.15 K. Following a previously described automated process [39] , the beads were rapidly dissolved in 6 mL of pressurized, heated D 2 O and the resulting solution was transferred within 2 s into a separator/infusion pump located inside an actively shielded 31-cm diameter horizontal bore 9.4 T magnet (Magnex Scientific, Abingdon, UK) [40] . The separator/infusion pump was prefilled with 0.6 mL of phosphate buffered saline and heparin. Subsequently, 1.0 mL of solution at physiological temperature and pH, with a 13 C polarization level of 13 ± 2%, was automatically injected into the femoral vein of the anesthetized animal in 5 s. To determine the influence of the administrated amount of acetate, the 1.0 mL bolus of hyperpolarized [1-13 C]acetate was injected at a dose ranging from 0.3 to 1.0 mmol/kg. sequence [41] , resulting in a non-localized proton line width of 80-120 Hz. The spectrometer was triggered to start acquisition at the beginning of the automated injection process. Series of single pulse acquisitions were sequentially recorded using 30°adiabatic RF excitation pulses (BIR-4) [42] , with 1 H decoupling using WALTZ [43] .
In vivo MRI and MRS
Free induction decays were acquired with 4129 complex data points over a 20 kHz bandwidth. All acquisitions were cardiac triggered and respiratory gated, resulting in a nominal T R between 3 and 3.5 s. The adiabatic pulse offset and power were calibrated to ensure that the RF excitation angle θ = 30°for all observed metabolites in the entire tissue of interest. Following in vivo data acquisition, a 200 μL liquid sample was extracted from the separator/infusion pump to retrospectively determine the precise injected [1-13 C]acetate concentration [35] . The blood volume of the animals was obtained using the relation between total blood volume and body weight published by Lee and Blaufox [44] allowing calculation of the blood 13 C acetate concentration.
Data analysis
A non-linear least-squares quantification algorithm (AMARES) implemented in the jMRUI software package was used to fit the dynamic 13 C MRS data [45] . The spectra were corrected for the phase and DC offset. Soft constraints were imposed to peak frequencies (182.55-182.65 ppm for acetate, 173.85-173.95 ppm for acetylcarnitine, and 179.65-179.75 ppm for citrate) and line widths (FWHM = 10-30 Hz), and the relative phases were fixed to zero.
The time courses of the quantified peak areas were analyzed with Matlab (The MathWorks, Natick, MA, USA) using the kinetic models described in the next sections. Correlation matrices indicative of the extent to which free parameters affect each other were calculated for all analyses. The signal decay of precursor and metabolites results from a combination of the effects of longitudinal relaxation (characterized by the time constant T 1 ), RF excitation, and biochemical conversion and all time courses were corrected for the effect of repeated RF excitations. The T 1 of [1-13 C]acetylcarnitine was set to 14.9 s, as previously determined in vivo [35] , and that of [5] [6] [7] [8] [9] [10] [11] [12] [13] C]citrate to 20 s [46] . The acetate signal decay was treated as free parameter. The 13 C labeling of acetate entering the myocardium was treated as an instantaneous enrichment to its maximum value using an exponential function.
Kinetic model of myocardial acetate metabolism
A kinetic model describing the dynamic 13 C labeling pattern following the metabolism of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate ( Fig. 1 ) was implemented. It consists of a system of coupled differential equations that can be depicted by a box diagram ( Fig. 2A) and are described as follows:
ACE, COA, CAR, and CIT represent the total metabolic pool size of acetate, acetylCoA, acetylcarnitine, and citrate, respectively. 13 ACE, 13 COA, 13 CAR, and 13 CIT represent the size of the corresponding 13 CAR , which is supported by the rapid 13 C exchange between acetylCoA and acetylcarnitine observed by Schroeder et al. [47] , the system simplifies to (Fig. 2B Methods for a detailed description of the model. The value of α is not required for determining V TCA , but based on the previous estimation that 60% of pyruvate-derived acetylCoA cycled through the acetylcarnitine pool before citrate formation [47] , the factor α is expected to be at most 1/0.6. This mathematical model is an extension of the model we have previously used to analyze hyperpolarized acetate metabolism in skeletal muscle [35] and in the heart [48] . As for most 13 C MRS experiments, the signals originating from different cellular compartments cannot be separated and the model assumes that all processes take place within the same cellular compartment. It must however be borne in mind that the pathways through which citrate and acetylcarnitine can be 13 C-labeled are restricted because of the short experimental time, and although it is very possible that some 13 C-citrate and 13 C-acetylcarnitine flow from the mitochondria to the cytosol, they are labeled while located in the mitochondria. In other words, the dynamics of 13 C incorporation into citrate and acetylcarnitine is independent of the final location of both metabolites as long as the experiment is short enough for not having them labeled through other pathways, and ultimately the 13 C signal that is measured is a direct readout of the 13 C incorporation into mitochondrial citrate and acetylcarnitine. In the heart, the observed acetate signal originates from both tissue and blood, compartments which cannot be distinguished. Three different modeling approaches were investigated (See also Supplemental Methods): in model 1 (Fig. 2B) , the three equations (Eqs. (5)- (7)) are used to fit the signal evolution of acetate, acetylcarnitine, and citrate with a total of 5 free parameters, namely, the decay rate of acetate (R 1,ACE1 ), V ACS , V IM , V TCA and the acetate input function F i . In model 2 (Fig. 2C) , only the time courses of the two downstream metabolites are fitted and the substrate signal is used as an input function, F i = 13 ACE(t), with V ACS , V IM and V TCA as free parameters. In model 3 (Fig. 2D) , the citrate signal evolution is solely fitted and the acetylcarnitine is taken as an input function, F i = 13 CAR 1 (t), with only two free parameters, namely, V IM and V TCA . The mathematical models were adjusted to the 13 C curves by non-linear regression using the Levenberg-Marquardt algorithm, coupled to a RungeKutta method to obtain numerical solutions of the ordinary differential equations that define each model. All numerical procedures were performed using Matlab. Fitted parameters are reported with standard deviation. The concentration of citrate was set to 1.48 μmol/g dry weight, as determined in healthy male Sprague Dawley rats fed ad libitum and weighing between 300 and 400 g [49] , i.e., in animals having precisely the same specifications as those used in the present study. Note that pool sizes might differ in animals with different metabolic states or disease and should be modified accordingly. A wet/dry weight ratio of 5.29 was assumed [50] . The pool sizes of acetate [ACE] and acetylcarnitine [CAR] were not set but incorporated in the estimated kinetic parameters of the model, i.e., k ACS = V ACS /[ACE] and k IM = V IM /[CAR], due to limited evidence of the stability of the ACE and CAR pool sizes during the experiment.
Results
The metabolism of acetate was detected in the healthy rat myocardium within the first minute after its administration. Following the injection of the hyperpolarized [1- 13 Fig. 3B and C) . The signal integral of the precursor and downstream metabolites were plotted as a function of time C MRS data. Both the acetylcarnitine and citrate resonances originate from the myocardial tissue, therefore models 2 and 3 describe uniquely the myocardial compartments. In model 1, an instantaneous enrichment of acetate was assumed, employing an exponential input function F i . In models 2 and 3, the input function was described by the 13 C labeling time course of acetate and acetylcarnitine respectively.
( Fig. 4A and B) . The evolution of the [5- 13 C]citrate signal was recorded with sufficient signal-to-noise ratio (SNR), to be significantly above the noise level for 7 out of the 10 experiments in which citrate was detected (SNR larger or equal to 3 in the absence of line broadening). After reaching a maximum signal integral 8 ± 3 s after the start of the injection (Fig. 4A) , the hyperpolarized [1-13 C]acetate signal decayed mono-exponentially with a time constant of 9.6 ± 1.6 s.
The maximum acetylcarnitine signal integral was recorded 15 ± 3 s after the beginning of the injection and the maximum citrate signal integral approximately 6 s later (Fig. 4B) Fig. 5A ). Although these results vary 3-fold, the estimation of V TCA provided by model 3 was clearly less dependent on other fitting parameters and therefore more robust (Fig. S1 ). This model only fits the dynamics of the formation of citrate while using the time course of acetylcarnitine as an input function. It is therefore independent of the infused substrate acetate and leads to a more consistent estimation of V TCA .
Similar k ACS values were deduced from both models 1 and 2, respectively 1.7 ± 0.4 and 1.8 ± 0.4 ms − 1 ( Table 2 , Fig. 5B ), and the k IM extracted from all three models ranged from 24.7 ± 3.9 to 37.4 ± 14.0 ms − 1 ( Table 2 , Fig. 5C ). The mean V TCA and k IM values exhibit a clear dependence on the model and their standard deviation decreases with the number of reduced free parameters (Table 2 , Fig. 5 ). In addition, the correlation matrices show that when the number of free parameters decreases, they become less dependent on one another (Fig. S1 ). Both these observations support that k IM and V TCA were best estimated using model 3. It was observed that neither V TCA nor k IM depends on the amount of injected substrate, but that k ACS decays with increasing acetate dose, displaying a Michaelis-Menten like trend (Fig. S2A) . The acetylcarnitine-toacetate ratio showed a similar trend as function of the injected acetate dose (Fig. S2B) and it scaled linearly with k ACS (Fig. S3) . The citrate-to-acetate ratio did not correlate with the injected acetate dose or with any other determined parameter, showing that a ratiometric approach cannot be used to estimate myocardial V TCA .
Discussion
This study reports for the first time the direct in vivo detection of a TCA cycle intermediate following myocardial metabolism of acetate. Through the time-resolved measurement of 13 C citrate, a direct estimate of the V TCA flux could be determined. As in most hyperpolarized 13 C MRS experiments, elevated substrate concentrations were required. In this study, the estimated maximum plasma concentration at the end of the bolus injection was between 3 and 15 mM, which immediately decayed after the bolus injection. In previous metabolic studies, 45 min-long acetate infusions have been used, leading to plasma concentrations up to 10 mM [16, 51] , and no adverse effects were reported in hyperpolarized MR studies with comparable doses of 13 C-acetate [35, 36, [52] [53] [54] . In the present study, all monitored physiological parameters remained stable before and after injection (Table 1) , and no adverse effects were observed following acetate administration. In contrast to earlier investigations in cardiac muscle performed at 2.35 T or 3 T [36, 52, 54] , the increased spectral resolution obtained at 9.4 T allowed for the direct observation of the [5- 13 C]citrate resonance, and illustrates the benefit and need for high field. The delayed observation of citrate with respect to acetylcarnitine is consistent with the role of carnitine as a shuttle for acetyl groups across the mitochondrial membrane, and as a mitochondrial buffer for excess acetylCoA. A similar evolution of the 13 C labeling of citrate was detected using the hyperpolarized carbohydrate [2-13 C]pyruvate [55] .
However, in these studies the mitochondrial uptake of pyruvate is mediated by PDH where acetylcarnitine acts as a buffer for excess acetylCoA, which was shown to be a rapid exchange process [56] . The acetylCoA resonance previously reported at 202 ppm after a 90°e xcitation in the mouse heart following the injection of hyperpolarized [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate could not be detected in the present study [36] . Detectable quantities of 13 C-labeled glutamate could be expected since 60%
of the 14 C activity measured 2 min after the injection of 14 C-labeled acetate was associated with glutamate while a mere 8% was found to come from TCA cycle metabolites [57] . It was nevertheless not possible to detect the [5] [6] [7] [8] [9] [10] [11] [12] [13] C]glutamate resonance in our experiments which was ascribed to the close proximity of the large [1-
13 C]acetate resonance (the glutamate resonance is expected 0.1-0.2 ppm upfield from the acetate resonance). It must be borne in mind that it should be possible to further increase the sensitivity of these experiments by enhancing the initial polarization level of the 13 C nucleus through the improvement of the acetate substrate preparation [58, 59] . The myocardial V TCA was estimated using the three different kinetic models. Two of the proposed models do not directly take into account the dynamics of the injected substrate and only depend on the evolution of the acetylcarnitine and citrate signals, which originate from the tissue compartment. By excluding the time evolution of the acetate signal, a substantial part of which originates from the vascular compartment, it was observed that the estimation of the metabolic parameters is affected (Table 2 ). Additionally, it was observed that the parameters determining the acetate signal evolution did not correlate with the kinetic parameters related to acetylcarnitine and citrate 13 C labeling (Fig. S1) , showing that the acetylcarnitine and citrate signal evolution are independent of the bolus dynamics of the injected substrate. The 13 C labeling kinetics of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetylcarnitine was however found to be dependent on the dose of injected hyperpolarized [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate. This dose dependence is consistent with the role of mitochondrial carnitine acetyltransferase and acetylcarnitine as buffer system for intramitochondrial acetylCoA. A similar dose dependence was reported in a previous study in rat skeletal muscle from which the in vivo ACS MichaelisMenten parameters could be derived [35] . Michaelis-Menten parameters were not determined in the present work because of the large contribution of the ventricular compartment to the acetate signal. A ratiometric analysis of hyperpolarized acetate metabolism was also performed in the earlier skeletal muscle study, showing that metabolic rates and fluxes can be estimated without the need for mathematical modeling [35] . A linear relationship between k ACS and the acetylcarnitine-to-acetate ratio was indeed observed, leading to a simple mathematical definition to convert the acetylcarnitine-toacetate ratio to a kinetic rate constant k ACS . In the present study, a linear relationship was also observed, but only between the acetylcarnitineto-acetate ratio and k ACS . This suggests that a ratiometric approach is appropriate to analyze the ACS activity. However, no correlation between the evolution of the citrate signal and the acetylcarnitine or acetate signal could be detected. A possible explanation for this absence of correlation might be related to the potential increase of the acetylCoA pool resulting from the large amount of injected acetate that could lead to the sequestration of CoA. Since no acetylCoA signal was detected and because of the rate limiting role of ACS previously observed [35] , it is rather hypothesized that the discrepancy is due to the fact that it is not possible to separate the acetylcarnitine signals originating from the cytosolic and mitochondrial compartments, which are very likely to have a different 13 C labeling dynamics. Regardless of the reason behind this absence of correlation, it indicates that it is not possible to use a ratiometric approach to derive V TCA and that the kinetics of the acetylcarnitine signal cannot be used as a marker of mitochondrial oxidative metabolism. Note that the use of adiabatic excitation pulses provided identical excitation and detection for all metabolites and enabled observation of true ratios independent of their location in Table 2 Estimated metabolic fluxes and rates found using the three described kinetic models. Data are given as mean values ± SEM with the corresponding percentage errors in brackets. The spread as well as the error percentage of the estimated kinetic parameters decreased with the reduced number of free parameters. According to the calculated correlation matrixes (Fig. S1 ), model 3 estimates V TCA with the least influence of the other estimated parameters. Note that model 3 only incorporates the labeling of myocardial metabolites and k ACS was therefore not determined since the dynamics of the acetate signal was not taken into account. the sensitive volume of the 13 C coil. Although single pulses without encoded spatial localization were used for data acquisition, potential signal contamination from the superficial muscle was excluded due to difference in kinetics of acetylcarnitine and absence of 13 C citrate in an earlier study performed in skeletal muscle [35] , as well as the absence of the 13 C acetylcarnitine resonance in the chest muscle in 13 C images of acetylcarnitine [52] . It has to be noted that if there would be contamination from surrounding muscle tissue, this would only attribute to the 13 C acetylcarnitine signal. Since the estimation of V TCA is independent on the kinetics of 13 C acetylcarnitine using model 3, which is only dependent on the 13 C citrate signal evolution, model 3 is most robust for 13 C localization or compartmentation uncertainties. In 13 C MRS studies, information about endogenous pool sizes is necessary to derive quantitative metabolic fluxes. These pool sizes can change as a result of diseases, altered nutritional states such as fasting [60] , or substrate injection, especially during the long infusion times necessary to perform thermally-polarized 13 C MRS experiments. In the present hyperpolarized 13 C MRS study, downstream metabolic pool sizes were most likely not notably modified within the 30-60 s following the injection of the acetate bolus, i.e., within the time window of the measurements. This is again supported by the rate limiting role of ACS on acetate metabolism [35] . Based on this hypothesis and using the previously determined citrate concentration (1.48 μmol/g dry weight) [49] , V TCA was estimated to be 6.7 ± 1.7 μmol · g − 1 · min − 1 (dry weight). Although this value is comparable to previously published fluxes determined from 13 C MRS or radioactive labeled carbon experiments performed during a long acetate infusion in perfused heart or in vivo and typically leading to V TCA comprised between 7.4 and 14 μmol · g −1 · min −1 (dry weight) [3, 15, 16, 61] , the values estimated in the present work correspond to the lower end of the range. This might at first appear counter-intuitive since the RPP recorded in this in vivo study (~50 k mm Hg min
; Table 1 ) was significantly larger than the reported RPP in earlier studies (~20 k to 30 k mm Hg min − 1 ) [3, 15] , and a larger V TCA is usually expected with increased RPP. A limitation of the present work is the absence of comparison with a gold standard method such as the measurement of oxygen consumption rate (MVO 2 ). Although reporting similar V TCA , the obtained MVO 2 varied between 16 (in vivo [15] ) and 29 to 31 μmol · g −1 · min − 1 (dry weight) (in perfused heart [3, 16, 61] ), suggesting a more efficient energy conversion in vivo. Future studies should incorporate such a comparison to validate the estimated values of V TCA obtained in the present study. It is hypothesized that the low V TCA measured in the present study could be a consequence of the drastically shorter time of hyperpolarized 13 C MRS experiments as compared to thermally-polarized 13 C MRS or radioactively labeled carbon experiments. This might imply that variations in V TCA resulting from myocardial conditioning to the infused substrate can be neglected, which highlight the potential benefit of the short time frame of hyperpolarized 13 C experiments for cardiac studies.
Conclusion
We showed that it is possible to estimate myocardial V TCA in vivo through the time-resolved 13 to values previously determined indirectly through the several-hour measurements of glutamate 13 C labeling, although the results obtained through hyperpolarized 13 C MRS might be more accurate because it provides an almost instantaneous readout after the injection of the non-physiological dose of acetate. We expect that dynamic 13 C MRS coupled to the injection of hyperpolarized [1-13 C]acetate can enable the measurement of metabolic changes during impaired heart function. Fatty acid metabolism could ideally be probed with longer-chain substrates such as palmitate in order to provide information on the dynamics of beta oxidation. However, although in vivo butyrate and octanoate metabolism was measured in the rat heart by hyperpolarized 13 C MR [32, 37, 62] , their shorter T 1 as compared to acetate limits even more the sensitivity and therefore the possibility for translation to human applications.
The clinical potential of hyperpolarized MR is widely recognized, in particular in cancer research [63] , and the first trial in patients using [1- 13 C]pyruvate demonstrated that this technology can provide unique metabolic information for diagnostic purposes [64] . The foreseen applications in cardiac imaging and their expected impact in cardiology have been recently discussed [65] [66] [67] . Although hyperpolarized [1-13 C]acetate would be a unique probe to determine V TCA in humans, it would require the use of a high-field MR scanner and high-order shim coils to resolve the [5-13 C]citrate peak. Considering the rather rapid spread of 7 T human MRI technology, it is nevertheless not excluded that the method herein proposed could be one day translated for human applications.
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